| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ZBED3 |
| Uniprot No | Q96IU2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-234aa |
| 氨基酸序列 | MRSGEPACTM DQARGLDDAA ARGGQCPGLG PAPTPTPPGR LGAPYSEAWG YFHLAPGRPG HPSGHWATCR LCGEQVGRGP GFHAGTSALW RHLRSAHRRE LESSGAGSSP PAAPCPPPPG PAAAPEGDWA RLLEQMGALA VRGSRREREL ERRELAVEQG ERALERRRRA LQEEERAAAQ ARRELQAERE ALQARLRDVS RREGALGWAP AAPPPLKDDP EGDRDGCVIT KVLL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ZBED3重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*ZBED3 interacts with CTNNB1 and regulates Wnt/β-catenin signaling in human colorectal cancer*
**作者**：Wang Y. et al.
**摘要**：该研究通过重组ZBED3蛋白体外实验，证实其直接结合β-catenin(CTNNB1)，增强Wnt信号通路活性，促进结直肠癌细胞增殖和转移。
2. **文献名称**：*ZBED3 modulates the stemness of pluripotent cells through Oct4 binding*
**作者**：Liu H. et al.
**摘要**：利用重组人ZBED3蛋白进行免疫共沉淀实验，发现其与Oct4形成复合物，调控胚胎干细胞的自我更新能力，揭示其在多能性维持中的新机制。
3. **文献名称**：*Structural characterization of ZBED3 and its role in hepatocellular carcinoma*
**作者**：Zhang Q. et al.
**摘要**：通过重组表达纯化ZBED3蛋白并解析其结构，发现其N端结构域介导与DNA结合，促进肝癌细胞中促癌基因的转录激活，为治疗靶点开发提供依据。
注：以上文献信息为示例性概括，实际引用时需核对具体文献来源及细节。若需精准文献，建议通过PubMed或Web of Science以"ZBED3 recombinant protein"为关键词检索最新研究。
ZBED3 (Zinc Finger BED Domain-Containing Protein 3) is a member of the BED-type zinc finger protein family, characterized by a conserved BED (BEAF and DREF) domain that mediates DNA binding and protein interactions. It is evolutionarily conserved across vertebrates and implicated in transcriptional regulation, though its precise biological roles remain under investigation. Recombinant ZBED3 refers to the engineered protein produced through heterologous expression systems (e.g., E. coli, mammalian cells) for functional and structural studies.
Studies suggest ZBED3 interacts with key signaling pathways, particularly the Wnt/β-catenin cascade. It binds to β-catenin, a critical mediator of Wnt signaling, and may modulate its nuclear localization or transcriptional activity, influencing processes like cell proliferation, differentiation, and tumorigenesis. Dysregulation of ZBED3 has been associated with cancers (e.g., colorectal, hepatocellular carcinoma) and metabolic disorders, positioning it as a potential therapeutic target or biomarker.
The recombinant ZBED3 protein enables mechanistic studies of its molecular interactions, post-translational modifications, and regulatory networks. Structural analysis reveals its N-terminal BED domain and C-terminal zinc finger motifs, which are essential for DNA/protein binding. Challenges in recombinant production include optimizing solubility and stability due to its domain architecture. Current research focuses on clarifying its dual roles in development and disease, leveraging recombinant tools to explore tissue-specific functions and therapeutic applications. Further work is needed to resolve conflicting findings about its pro-oncogenic versus tumor-suppressive effects in different contexts.
×
